Developing novel biological therapies targeting myeloid malignancies
The Wang Lab conducts acute myeloid leukemia (AML) preclinical research to find novel, synergistic treatments that target AML cells and leukemic stem cells in normal and hypoxic conditions.
Our research focuses on a variety of mechanisms, including DNA repair, DNA damage, apoptosis, autophagy, mitophagy, and cell cycle.
Join our team!
We currently seek candidates for a faculty position, Assistant or Associate Professor, specializing in Leukemia/Benign Hematology.
AML is a highly heterogeneous disease, with a vital need for novel treatments that are targeted and better tolerated.Read the research
We’re studying several promising new drugs, including combination therapy with crenolanib and frontline treatment with gilteritinib.See the science
Get to know our principal investigator and lab members.Meet our team
Check out the latest articles and abstracts from Dr. Wang’s team.View citations
"If you're diagnosed with cancer, you can't wait six to 12 months for the FDA to approve a drug. You need it now."
Connect with the Wang Lab
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263